Cancer vaccines represent an innovative approach in tumor immunology, aiming to activate the immune system to recognize and target cancer cells. These vaccines introduce tumor-associated antigens that stimulate an immune response specifically against cancerous cells. By engaging T cells and other immune components, cancer vaccines help the body identify and destroy tumor cells while sparing healthy tissue. This immunotherapeutic approach is less invasive than traditional cancer treatments, offering potential for fewer side effects. Cancer vaccines are increasingly used alongside therapies like immune checkpoint inhibitors, creating a synergistic effect that can significantly enhance patient outcomes. As research advances, cancer vaccines hold promise for treating various malignancies, marking a shift toward more personalized, targeted, and effective cancer therapies.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria